There were 712 press releases posted in the last 24 hours and 170,993 in the last 365 days.

Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements

/EIN News/ -- NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed.

Ohr Pharmaceutical Contact:
Investor Relations                                         
OP: 212-682-8452


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.